University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Biochemistry -- Faculty Publications

Biochemistry, Department of

10-29-2018

Mouse genome-wide association studies and systems genetics
uncover the genetic architecture associated with hepatic
pharmacokinetic and pharmacodynamic properties of a
constrained ethyl antisense oligonucleotide targeting Malat1
Elaine Pirie
Carlsbad, California

Shayoni Ray
Carlsbad, California

Calvin Pan
University of California

Wuxia Fu
Carlsbad, California

Andrew F. Powers
Carlsbad, California
Follow this and additional works at: https://digitalcommons.unl.edu/biochemfacpub
Part of the Biochemistry Commons, Biotechnology Commons, and the Other Biochemistry, Biophysics,
See
page Biology
for additional
authors
and next
Structural
Commons

Pirie, Elaine; Ray, Shayoni; Pan, Calvin; Fu, Wuxia; Powers, Andrew F.; Polikoff, Danielle; Miller, Colton M.;
Kudrna, Katrina M.; Harris, Edward N.; Lusis, Aldons J.; Crooke, Rosanne M.; and Lee, Richard G., "Mouse
genome-wide association studies and systems genetics uncover the genetic architecture associated with
hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense
oligonucleotide targeting Malat1" (2018). Biochemistry -- Faculty Publications. 384.
https://digitalcommons.unl.edu/biochemfacpub/384

This Article is brought to you for free and open access by the Biochemistry, Department of at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Biochemistry -- Faculty
Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors
Elaine Pirie, Shayoni Ray, Calvin Pan, Wuxia Fu, Andrew F. Powers, Danielle Polikoff, Colton M. Miller,
Katrina M. Kudrna, Edward N. Harris, Aldons J. Lusis, Rosanne M. Crooke, and Richard G. Lee

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
biochemfacpub/384

RESEARCH ARTICLE

Mouse genome-wide association studies and
systems genetics uncover the genetic
architecture associated with hepatic
pharmacokinetic and pharmacodynamic
properties of a constrained ethyl antisense
oligonucleotide targeting Malat1
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111

Elaine Pirie ID1☯, Shayoni Ray1☯¤, Calvin Pan ID2, Wuxia Fu1, Andrew F. Powers3,
Danielle Polikoff1, Colton M. Miller4, Katrina M. Kudrna4, Edward N. Harris ID4, Aldons
J. Lusis2, Rosanne M. Crooke1, Richard G. Lee1*
1 Cardiovascular Antisense Drug Discovery Group, Ionis Pharmaceuticals, Carlsbad, California, United
States of America, 2 Department of Human Genetics, University of California, Los Angeles, Los Angeles,
California, United States of America, 3 Exploratory Drug Discovery Group, Ionis Pharmaceuticals, Carlsbad,
California, United States of America, 4 Department of Biochemistry, University of Nebraska-Lincoln, Lincoln,
NE, United States of America

OPEN ACCESS
Citation: Pirie E, Ray S, Pan C, Fu W, Powers AF,
Polikoff D, et al. (2018) Mouse genome-wide
association studies and systems genetics uncover
the genetic architecture associated with hepatic
pharmacokinetic and pharmacodynamic properties
of a constrained ethyl antisense oligonucleotide
targeting Malat1. PLoS Genet 14(10): e1007732.
https://doi.org/10.1371/journal.pgen.1007732
Editor: Gregory S. Barsh, Stanford University
School of Medicine, UNITED STATES
Received: April 10, 2018
Accepted: October 1, 2018
Published: October 29, 2018
Copyright: © 2018 Pirie et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All HMDP liver
microarray files are available from the NCBI GEO
database (accession ID GSE16780).
Funding: Ionis Pharmaceuticals Inc http://www.
ionispharma.com/ approved and sponsored the
study design, data collection, analysis, and
preparation of the manuscript. Supported authors
EP, SR, WF, AFP, DP RMC, and RGL. The National
Institute of Health sponsored data collection.

☯ These authors contributed equally to this work.
¤ Current address: Radiation Biophysics and Cancer Genomics, Space Biology Research Branch, NASA
Ames Research Center, Moffett Field, California, United States of America
* RLee@ionisph.com

Abstract
Antisense oligonucleotides (ASOs) have demonstrated variation of efficacy in patient populations. This has prompted our investigation into the contribution of genetic architecture to
ASO pharmacokinetics (PK) and pharmacodynamics (PD). Genome wide association
(GWA) and transcriptomic analysis in a hybrid mouse diversity panel (HMDP) were used to
identify and validate novel genes involved in the uptake and efficacy of a single dose of a
Malat1 constrained ethyl (cEt) modified ASO. The GWA of the HMDP identified two significant associations on chromosomes 4 and 10 with hepatic Malat1 ASO concentrations. Stabilin 2 (Stab2) and vesicle associated membrane protein 3 (Vamp3) were identified by ciseQTL analysis. HMDP strains with lower Stab2 expression and Stab2 KO mice displayed
significantly lower PK than strains with higher Stab2 expression and the wild type (WT) animals respectively, confirming the role of Stab2 in regulating hepatic Malat1 ASO uptake.
GWA examining ASO efficacy uncovered three loci associated with Malat1 potency: Small
Subunit Processome Component (Utp11l) on chromosome 4, Rho associated coiled-coil
containing protein kinase 2 (Rock2) and Aci-reductone dioxygenase (Adi1) on chromosome
12. Our results demonstrate the utility of mouse GWAS using the HMDP in detecting genes
capable of impacting the uptake of ASOs, and identifies genes critical for the activity of
ASOs in vivo.
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Author summary
Previous work in the clinic has clearly demonstrated differential patient response to antisense oligonucleotide (ASO) drugs. However, to date there has been no systematic evaluation of genes associated with this response in vivo. In this study, we utilized an advanced
genetic methodology in mice to identify genes involved with the heterogeneity in both
accumulation and potency of an ASO targeting metastasis associated lung adenocarcinoma transcript 1 (Malat1) in liver. Detailed analysis of ASO functionality in livers from
100 genetically distinct strains of inbred mice treated with either Malat1 or control ASO
led to the selection of specific genetic regions associated with variation in ASO uptake and
potency. Specifically, we identified regions on chromosomes 4 and 10 which highlighted
two genes associated with variations in hepatic drug accumulation. Further, we established three regions on chromosome 4 and 12 linked to three genes associated with variability in hepatic ASO efficacy. We carried out additional functional validation of the
isolated genes in mouse models and cell lines and confirmed that this methodology can be
used to identify genes affecting ASO drug response. These results are particularly important for the design of antisense drugs with improved efficacy, safety, and tolerability.

Introduction
Antisense oligonucleotides (ASOs) are highly selective and potent therapeutic agents which
has proven effective in treating a variety of disease states including cancer, viral infection and
cardio-metabolic, inflammatory and neurological diseases [1–7]. Antisense technology uses
short synthetic (12–24 mers), chemically modified DNA-like oligonucleotides to alter the
intermediary metabolism of RNAs. The most widely exploited mechanism of ASO functionality is the degradation of complementary mRNA utilizing ribonuclease H1 (RNase H1), thereby
preventing the translation of the associated protein(s) [8]. The evolution of this technology
over the past 30 years has led to the development of a variety of ASO modifications resulting in
greater stability, potency, affinity, and reduced toxicity [9, 10].
While these therapeutic agents have proven to be effective against disease in the clinic, significant variability in ASO response has been reported in several of the drugs [11, 12]. For
example Kynamro, a second-generation 2´ methoxyethyl ASO targeting human apoB, has
been approved by the FDA for use as an adjunct with first-line therapies to reduce apoB and
total cholesterol in homozygous familial hypercholesterolemia (FH) patients. In Phase 3 trials,
FH patients who were administered 200 mg/week of the drug observed reductions in plasma
LDL-C levels ranging from 2% to –82% [1]. Differences in observed efficacy is not unique to
the ASO platform: genetic make-up may account for 20%-95% of overall variability of therapeutic agents in general [13]. Importantly, previous research has indicated that pathways leading to ASO tissue accumulation and pathways driving ASO activity may be segregated due to
the presence of ASO ‘sinks’, trapping ASO within endocytotic compartments [14, 15]. To date,
no in vivo systematic interrogation of the role of genetic architecture on ASO accumulation
and potency has been performed.
Genome-wide association studies (GWAS) provide 1) hypothesis-free mapping and 2) the
identification of causal variants within the genome that contribute to the variability of a complex trait. The utilization of this system has allowed the detection of single-nucleotide polymorphisms (SNPs) leading to novel mechanistic insights and the identification of hundreds of
genes potentially causal for human pathophysiological states such as diabetes, cancer and
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numerous cardiovascular diseases [16, 17]. Association studies in mouse models provide multiple advantages over large scale analyses in human populations, including cost effectiveness,
reproducibility of results and the reduced impact of environmental factors. The hybrid mouse
diversity panel (HMDP) is one such resource. It consists of over 100 genetically unique inbred
mouse strains– 30 “classical inbred” strains, in addition to over 70 “recombinant inbred”
strains. The recombinant inbred strains were derived from the F1 crosses of eight inbred
“founder strains” and are able to offer important insights into genetically-derived differences
in phenotype among inbred mice. The strains making up the HMDP are genotyped at 140,000
high quality SNPs [18–20], with sufficient power to detect traits contributing to 10% of overall
phenotypic variance. GWAS carried out with the HMDP have identified significant SNPs in a
wide variety of phenotype measurements such as NAFLD, bone mineral density, insulin resistance, obesity and heart failure [21–25].
To better understand the genetic variability and genomic variants that are associated with
ASO uptake and potency, we employed GWAS and transcriptomic analysis of the HMDP
using a generation 2.5 2´, 4´- constrained 2´-O- ethyl (cEt) ASO [9] targeting the murine long
noncoding RNA metastasis associated lung adenocarcinoma transcript 1 (Malat1). Following
a single dose of this ASO, both hepatic Malat1 expression and tissue accumulation were evaluated in 100 HMDP strains. Significant intra-strain variability was observed in both hepatic
Malat1 ASO potency and accumulation. Using Factored Spectrally Transformed Linear Mixed
Model (FastLMM) [26, 27], we identified two loci on chromosomes 4 and 10 associated with
hepatic Malat1 ASO accumulation. Systems genetic analysis determined these loci contributed
to expression of Stabilin 2 (Stab2) on chromosome 10 and vesicle associated membrane protein 3 (Vamp3) on chromosome 4. Additionally, we identified three loci, two on chromosome
12 and one on chromosome 4, associated with variation in hepatic Malat1 ASO potency. Rho
associated coiled-coil containing protein kinase 2 (Rock2) and Aci-reductone dioxygenase
(Adi1) were identified as high confidence candidate genes regulating ASO PD in chromosome
12, while UTP11 small subunit processome component (Utp11l) was identified on chromosome 4. Additional in vitro studies validated Rock2 contributions to the hepatic potency of the
Malat1 ASO. Our results demonstrate that genetic variation impacts ASO PK/PD and validates
the use of the HMDP GWAS in advancing our understanding of the molecular mechanisms
that contribute to ASO biology.

Results
Genome-wide association analysis of hepatic ASO accumulation
To identify genomic regions associated with Malat1 ASO PK, 6-week-old male mice from the
HMDP were administered a single 2 mg/kg dose of either the constrained ethyl (cEt) Malat1
ASO (ION 556089) or the cEt control ASO (ION 549144), which does not target any known
coding gene in the mouse genome (S1 Fig). A wide spectrum in hepatic accumulation of the
Malat1 ASO (Fig 1A) was observed, ranging from 0.29 μg/g (Akr/J mice) to 2.17 μg/g (BXD31/
TyJ mice). This variability did not correlate to average body (Fig 1B) or liver weights (Fig 1C).
Association analysis was performed using FASTLmm in which adjusted association p-values were calculated for 108,064 SNPs with minor allele frequency of > 5% (p < 0.05 genomewide equivalent for GWA using FASTLmm in the HMDP is p = 4.1 x 10−6, -log10p = 5.39). At
this threshold, genome-wide significant loci associated with variation in hepatic Malat1 ASO
accumulation (Fig 2) were identified on chromosomes 4 and 10 (rs32062485, p = 8.56x10-10;
rs29346676, p = 1.93x10-6) (Table 1). The chromosome 4 locus contained 7 genes within the
linkage disequilibrium (LD) block, out of which 5 were expressed in liver (Table 2). The chromosome 10 locus rs29364476 (Table 3) contained 11 genes, 6 of which were expressed in liver.
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Fig 1. Effects of genetic background on hepatic accumulation of Malat1 ASO in the HMDP. (A) 6-week-old male mice from 100 HMDP strains (n = 5/strain/
treatment) were dosed with a single 2 mg/kg dose of either Malat1 ASO (ION 556089) or control ASO (ION 549144). Livers were harvested after 72 hours and PK
analysis performed as described. Results are presented as mean ± S.E.M. (B) Correlation of ASO PK with average body weight (BW) in grams and (C) average liver
weight (expressed as % BW).
https://doi.org/10.1371/journal.pgen.1007732.g001

These genes included Stab2, a type I transmembrane hyaluronan receptor involved in multiple
cellular processes that has been previously implicated in affecting hepatic accumulation of
phosphorothioate ASOs [28, 29].

Systems genetics analysis of additional PK associated SNPs
Since the majority of SNPs identified in the HMDP occur in noncoding regions, it became
imperative to not only identify genes within the same LD block, but also those with expression
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Fig 2. GWA results for hepatic Malat1 ASO concentrations in the HMDP. Manhattan plot showing the–log10 of the
association p-values (-logp) for hepatic accumulation of Malat1 ASO in 100 HMDP strains. Each chromosome is
plotted on the x-axis in alternating light and dark colors. Genome-wide significance threshold line is shown in blue
(-logp = 5.39).
https://doi.org/10.1371/journal.pgen.1007732.g002

regulated by the identified SNPs. To this end, global gene expression microarrays conducted
using the liver tissue of chow-fed male mice from 95 HMDP strains [30] (NCBI GEO
GSE16780) were used in conjunction with the SNP data to generate a list of expression quantitative trait loci (eQTL). The eQTL analysis led to the identification of cis- (within 1 Mb of the
peak SNP) and trans- (greater than 1 Mb from the peak SNP) regulated genes corresponding
to the SNPs at Chromosome 4 (S1 Table) and Chromosome 10 (S2 Table). Vesicle associated
membrane protein 3 (Vamp3) was determined to be strongly regulated in cis by identified
chromosome 4 SNP rs32062485 (p = 2.4 x 10−28, S1 Table and S3A Fig) and in trans by identified chromosome 10 SNP rs29346676 (p = 6.3 x 10−8, S2 Table).

Validation of Stab2’s role in hepatic ASO accumulation
Stab2, a previously determined key player in ASO accumulation [28, 29, 31], was identified
within the LD block of peak chromosome 10 SNP rs29364476, and was further determined to
be strongly regulated in cis by this SNP (p = 3.48x10-6, Fig 3A, S2 Table). Systems analysis of
the peak SNP demonstrated a significant difference in hepatic ASO concentration dependent
upon the genotype of SNP rs29364476 (Fig 3B). Based on the variation of hepatic expression of
Stab2 across the 100 strains, we next identified the strains expressing low and high levels of
Stab2 (Fig 3C, S2 Fig) and compared the hepatic drug tissue accumulation between the two
groups via LCMS. Mice with lower Stab2 expression accumulated significantly less drug compared to strains with higher Stab2 expression (Fig 3C). To further confirm the role of Stab2,
we utilized previously published Stab2-/- mice [28]. Compared to WT (Stab2+/+ littermates),
Stab2-/- mice demonstrated significantly less ASO accumulation in both liver and spleen after a
single Malat1 ASO dose (Fig 3D and 3E). Importantly, there was a trend but no significant difference in the ASO efficacy between the Stab2+/+ and Stab2-/- mice (Fig 3F).
Table 1. List of Peak SNP results for hepatic Malat1 ASO accumulation in the HMDP.
Trait

Sex

Chr.

Peak SNP

Position

p Value

LD

No. of Hepatic Genes

Hepatic MALAT-1 accumulation

male

4

rs32062485

153939301

8.56E-10

153.9–154.4

5

Hepatic MALAT-1 accumulation

male

10

rs29364476

87351304

1.90E-06

867.3–882.1

6

https://doi.org/10.1371/journal.pgen.1007732.t001
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Table 2. List of genes within the linkage disequilibrium block for identified SNP rs32062485 in chromosome 4.
Gene Symbol

Gene Name

Expression

A430005L14Rik

RIKEN cDNA A430005L14 gene

Hepatic

Dffb

DNA Fragmentation Factor, beta subunit

Hepatic

Cep104

Centrosomal Protein 104

Hepatic

Lrrc47

Leucine rich repeat containing 47

Hepatic

Smim1

Small Integral Membrane Protien 1

Hepatic

BC039966

cDNA sequence BC039966

Non-Hepatic

Ccdc27

Coiled-coil domain containing 27

Non-Hepatic

https://doi.org/10.1371/journal.pgen.1007732.t002

Validation of Vamp3’s role in hepatic ASO accumulation
The Vamp3 gene product is a small soluble N-ethylmaleimide-sensitive factor attachment protein receptors with Arg/R residue (R-SNARE) highly expressed in the liver and known to play
a vital role in providing specificity in catalyzing the fusion of vesicles to their target membrane
[32]. Since Vamp3 plays a key role in vesicular transport, a process that has been implicated in
ASO uptake, we investigated the putative role of Vamp3 in hepatic ASO PK. As with Stab2,
systems analysis of the peak SNP rs32062485 demonstrated a significant difference in hepatic
ASO concentrations based on the genotype distribution at that SNP (Fig 4B). In order to isolate the effect of Vamp3 expression and reduce the input of confounding genes, we utilized the
BXD subset of the HMDP panel, which is derived from a single founder pair cross and shown
previously to provide sufficient power in GWAS [23]. Our analyses determined that BXD
strains with relatively lower Vamp3 expression demonstrated significantly lower hepatic ASO
concentrations (Fig 4C, S3A Fig).
In order to experimentally validate the role of Vamp3 in ASO accumulation, we utilized a
mouse hepatocellular SV40 large T-antigen carcinoma (MHT) cell line, which is capable of
free ASO uptake. Cells were transduced with shRNA targeting either Vamp3 or a scrambled
control, then assessed for Vamp3 expression reduction by QPCR (Fig 4D). Cells were subsequently treated with 250 ug Malat1 ASO for 24 hours. LCMS of cells transduced with shRNA
targeting Vamp3 demonstrated a significant decrease in ASO accumulation, validating Vamp3
as an important mediator of ASO uptake (Fig 4D).

Genome-wide association analysis of hepatic ASO activity
There was also marked variability in hepatic Malat1 ASO activity (Fig 5A), ranging from 82%
target reduction in BXA14/PgnJ mice to essentially no activity (0%) in 129X1/SvJ mice. These
Table 3. List of genes within the linkage disequilibrium block for identified SNP rs29364476 in chromosome 10.
Gene Symbol

Gene Name

Expression

Hsp90b1 (Rik)

Heat shock protein 90, beta

Hepatic

Stab2

Stabilin 2

Hepatic

Igf1

Insulin-like growth factor 1

Hepatic

Pah

Phenylalanine hydroxylase

Hepatic

Nup37

Nudeoporin 37

Hepatic

Ccdc53

Coiled-coil domain containing 53

Hepatic

Nt5dc3

5’-nucleotidase domain containing 3

Non-Hepatic

Ascl1

Achaete-scute complex homolog 1

Non-Hepatic

Pmch

Pro-melanin-concentrating hormone

Non-Hepatic

Parpbp

PARP1 binding protein

Non-Hepatic

Dram1

DNA-damage regulated autophagy modulator 1

Non-Hepatic

https://doi.org/10.1371/journal.pgen.1007732.t003
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Fig 3. Systems genetics analysis and validation of Stab2 for influencing hepatic accumulation of the Malat1 ASO. (A) Chromosome 10 plot for Stab2 displaying all
significant SNPs (-log10 of p) for ASO uptake on Chromosome 10. Red arrow indicates position of gene. (B) Distribution of Malat1 ASO accumulation based on
genotype associated SNP on chromosome 10 (rs29364476). Box and whisker plot depicting mean and distribution. (C) HMDP strains with lower hepatic Stab2
expression (S2 Fig) demonstrate lower hepatic ASO accumulation than those with higher Stab2 expression. Mean ± SEM, � p � 0.05 unpaired t-test, Welch’s correction.
(D) Hepatic accumulation of Malat1 ASO was assessed in Stab2-/- and WT mice 72 hours after single Malat1 ASO dose of 2 mg/kg. Hepatic concentration of ASO is
significantly lower in livers of Stab2-/- mice as compared to WT mice. Mean ± SEM, � p � 0.05 unpaired t-test. (E) Splenic accumulation of Malat1 ASO was assessed in
Stab2-/- and WT mice 72 hours after single Malat1 ASO dose of 3mg/kg. Data shows mean ± S.E.M, � p� 0.05 �� p � 0.01, unpaired t-test. (F) Expression of hepatic
Malat1 mRNA by QPCR after treatment with Malat1 ASO compared to a control ASO. There is no significant difference between the Stab2+/+ and Stab-/- mice,
unpaired t-test. Data shows mean ± S.E.M.
https://doi.org/10.1371/journal.pgen.1007732.g003

results were confirmed via in situ immunostaining for Malat1 mRNA in ASO treated liver
samples from the AXB5/PgnJ and BXD39/TyJ mice (S4 Fig). This genetic variability in ASO
activity did not correlate with either average body or liver weights (Fig 5B and 5C) or hepatic
Malat1 mRNA expression in control ASO treated mice (Fig 5D and S5 Fig). We also performed a dose response study and a time-course analysis of Malat1 ASO activity in three classic inbred strains of mice and results from both the studies were consistent with the single
dose Malat1 experimental results (S4B and S4C Fig).
To identify genomic loci responsible for the variation in potency, we performed FASTLmm
analysis with the genome-wide significance threshold of 4.1 x 10−6 and identified three loci
(Fig 6A, Table 4): two loci on chromosome 12 (rs29210579 p = 5.4 x 10−6 and rs229212236
p = 5.5 x 10−6), which were 8.4 Mb apart. rs29210579 contained 9 genes with in the LD block,
7 of which are expressed in liver, while rs29212236 contained 6 genes within the LD block with
4 expressed in liver (Tables 5 and 6). The remaining locus was one on chromosome 4
(rs27549337, p = 1.33x10-6), with one hepatic gene in the LD block (Table 7).
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Fig 4. Systems genetics analysis and validation of Vamp3 for influencing hepatic accumulation of the Malat1 ASO. (A)
Chromosome 4 plot for Vamp3 displaying all significant SNPs (-log10 of p) on Chromosome 4 for ASO uptake. Red arrow indicates
position of gene. (B) Distribution of hepatic Malat1- ASO accumulation based on genotype distribution at peak SNP associated with
ASO accumulation on chromosome 4 (rs32062485) data shows mean ± SEM, � p � 0.05 unpaired t-test. (C) BXD strains with lower
hepatic Vamp3 expression (S3A Fig) displays significantly lower hepatic accumulation of Malat1 ASO. Data shows mean ± S.E.M, �
p � 0.05, unpaired t-test. (D) MHT cells transduced with shRNA targeting either scrambled control (shCtrl) or Vamp3
(sh_Vamp3_1, sh_Vamp3_2) were treated with 250 ug Malat1 ASO for 24 hours, then assessed for ASO uptake via LCMS. Cells with
reduced Vamp3 expression had significantly lower ASO uptake. Data shows mean ± S.E.M, ��� p< 0.0001 with one way ANOVA,
Dunnett’s multiple compairisons test.
https://doi.org/10.1371/journal.pgen.1007732.g004

Systematic identification, systems genetics analysis and validation of genes
associated with Malat1 ASO activity
Consistent with the accumulation studies described above, we again performed transcriptomic
(eQTL) analyses using hepatic microarray expression data, accessible on NCBI GEO
(GSE16780). This effort resulted in a list of genes that were in cis and trans regulation by the
peak SNP at chromosome 4 (rs27549337) and two on chromosome 12 (rs29210579 and
rs29212236) (S3, S4 and S5 Tables).
Analysis of SNP rs27549337 on chromosome 4 indicated that variability of the ASO activity
associated with this SNP was not associated with endogenous Malat1 mRNA expression variability, further validating the systems genetics approach (Fig 5B and 5C). Four genes were
revealed to be regulated by that SNP in cis. Three of these genes are expressed in liver, and
intriguingly the list includes Utp11l, small subunit processome component [33]. This protein
is ubiquitously expressed and is involved in active pre-RNA processing complex, making it an
appealing target [34].
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Fig 5. Large genetic variation in hepatic potency of the Malat1 ASO among male mice. (A) Hepatic Malat1 expression in HMDP strains following a single dose of
2mg/kg of the Malat1 and control ASOs. Results are presented as mean ± S.E.M (% Control ASO). (B) Correlation of hepatic Malat1 expression with average body
weight (BW) in gm and (C) Average liver weight (expressed as % BW) (D) Correlation of hepatic Malat1 knockdown and basal level of Malat1 expression in liver of the
100 strains (as compared to C57BL/6J).
https://doi.org/10.1371/journal.pgen.1007732.g005

Systems analysis of the chromosome 12 SNP rs29210579, as with the chromosome 4 SNP,
indicated that the variability in Malat1 ASO activity associated with the SNP was not due to
basal Malat1 mRNA expression level differences (Fig 6A and 6B). We identified Rock2 and
Lpin1 as high-confidence candidate genes because they both were (i) expressed in the liver, (ii)
present in the LD region (Table 6) and, (iii) strongly regulated in cis by rs29210579
(p = 1.27x10-10 S4 Table).
To assess the function of Lpin1 in modulating ASO potency, we again utilized a mouse
hepatocellular SV40 large T-antigen carcinoma (MHT) cell line [35], with non-silencing (NS)
siRNA or Lpin1 siRNA for 48 h. Treatment with Lpin1 siRNA yielded a 58% reduction in target gene expression (S6A and S6B Fig). Subsequent exposure of siRNA treated cells to Malat1
ASO for 72 hours did not reveal differential ASO activity (S6C and S6D Fig) suggesting that
Lpin1 is not playing a significant role in Malat1 ASO activity under these conditions.
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Fig 6. GWA results and validation for hepatic Malat1 ASO activity in the HMDP. (A) Manhattan plot showing
the–log10 of the association p-values (-logp) for hepatic expression of Malat1 mRNA in 100 HMDP strains. Each
chromosome is plotted on the x-axis in alternating light and dark colors. Genome-wide significance threshold line is
shown in blue (-logp = 5.39). (B) Distribution of hepatic Malat1 expression based on genotype distribution at peak
SNP rs27459337. Data shows box-and-whisker plot showing mean and distribution, unpaired t-test, �� p�0.01. (C)
Distribution of basal hepatic Malat1 expression based on genotype distribution at rs27459337. Box-whisker-plot
showing mean and distribution, unpaired t-test, n.s.
https://doi.org/10.1371/journal.pgen.1007732.g006

Validation of Rock2’s role in hepatic ASO activity
To inhibit the kinase activity of Rock, MHT cells were treated for 24 h with Y27632, a potent
pharmacological inhibitor of Rock1 and Rock2. In the presence of Y27632 a significant
decrease in phospho-myosin light chain 2 (MLC2) was observed (S6E Fig), consistent with
inhibition of Rock kinase activity. Subsequent exposure of treated cells to Malat1 ASO revealed
a significant difference in ASO activity in treated vs nontreated MHT cells (Fig 7D), validating
our finding that Rock2 regulation impacts ASO activity.

Validation of Adi1’s role in hepatic ASO activity
We also considered other cis-genes that may affect ASO PD. Aci-reductone dioxygenase
(Adi1) was the gene most significantly regulated (p = 3.4x10-38, S5 Table and Fig 7A) in cis by
Table 4. List of peak SNP results for hepatic Malat1 ASO activity in the HMDP.
Trait

Sex

Chr.

Peak SNP

Position

p Value

LD

No. of Hepatic Genes

Hepatic Malat1 expression

male

12

rs29210579

16857727

5.40E-06

138.5–170.6

7

Hepatic Malat1 expression

male

12

rs29212236

25280545

5.50E-06

252.8–235.1

4

Hepatic Malat1 expression

male

4

rs27549337

126768234

1.33E-06

126.7–127.2

1

https://doi.org/10.1371/journal.pgen.1007732.t004
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Table 5. List of genes within the linkage disequilibrium block for identified SNP rs29210579 in chromosome 12.
Gene
Symbol

Gene Name

Expression

Psmb2

proteasome (prosome, macropain) subunit, beta type 2

Hepatic

AU040320

expressed sequence AU040320

Hepatic

Zmym4

zinc finger, MYM-type 4

Hepatic

Sfpq

splicing factor proline/glutamine rich (polypyrimidine tract binding protein
associated)

Hepatic

Zmym1

zinc finger, MYM domain containing 1

Hepatic

Zmym6

zinc finger, MYM-type 6

Hepatic

Tmem35b

transmembrane protein 35B

Hepatic

Tfap2e

transcription factor AP-2, epsilon

NonHepatic

Ncdn

neurochondrin

NonHepatic

https://doi.org/10.1371/journal.pgen.1007732.t005

chromosome 12 SNP rs29212236. While Adi1 is primarily known for its role in methionine
metabolism, the human orthologue has recently been implicated to a novel role in nuclear
mRNA processing possibly by modulating splicing factor U1-70K-related functions [36]. Systems analysis of Adi1 reveals that strains with higher Adi1 had lower Malat1 ASO activity (Fig
8B and 8C), thus suggesting that interactions between several genetic factors might affect the
potency of ASO drugs.
In order to futher validate the role of Adi1 in ASO activity, MHT cells were treated with
either a scrambled siRNA or Adi1 siRNA for 24 hrs, washed, and subsequently exposed to
increasing concentrations of Malat1 ASO (Fig 8D). Treatement with Adi1 siRNA showed a significant reduction in ASO activity compared to control siRNA, validating Adi1 as an important mediator of ASO efficacy in liver (Fig 7E).

Discussion
Antisense drugs have been successfully used as research tools and as therapeutic agents in the
clinic for decades. While the basic uptake and activity properties of these drugs have been elucidated [37], ongoing research efforts seek to identify factors that affect the distribution, efficacy, safety and tolerability of these therapeutic agents [38]. Advances in ASO medicinal
chemistry have drastically enhanced activity, allowing significantly lower doses of drug to be
administered in the clinic. Recently, research has been increasingly directed toward understanding the mechanisms of oligonucleotide uptake [39]. Briefly, once ASOs reach the cell surface they are internalized via endosomal vesicles, ultimately reaching their intended mRNA
target either in the nucleus or cytosol [14, 39, 40]. It is generally accepted that some pathways
of internalization and trafficking are productive, i.e leading to a pharmacological effect, while
Table 6. List of genes within the linkage disequilibrium block for identified SNP rs2912236 in chromosome 12.
Gene Symbol

Gene Name

Lpin1

lipin 1

Expression
Hepatic

Rock2

Rho-associated coiled-coil containing protein kinase 2

Hepatic
Hepatic

E2f6

E2F transcription factor 6

Greb1

gene regulated by estrogen in breast cancer protein

Hepatic

Ntsr2

neurotensin receptor 2

Non-Hepatic

Pqlc3

PQ loop repeat containing

Non-Hepatic

https://doi.org/10.1371/journal.pgen.1007732.t006
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Table 7. List of genes within the linkage disequilibrium block for identified SNP rs27549337 in chromosome 4.
Gene Symbol

Gene Name

Expression

Gm17746

predicted gene, 17746

Hepatic

https://doi.org/10.1371/journal.pgen.1007732.t007

others are pharmacologically non-productive ‘sinks’ [41, 42]. Several structural, nucleic acid
binding and chaperone proteins have been shown to bind to ASOs and influence intracellular
localization and trafficking within the cell [42, 43]. Most importantly, some of these interactions are known to impact ASO therapeutic potency [4].
Here we investigate the role of genetics in modulating hepatic Malat1 ASO uptake and
activity in mice. Results from our studies demonstrate that after a single dose of a Malat1 cEtmodified ASO, hepatic distribution of the drug and activity vary significantly among the 100
genetically unique HMDP strains. This considerable variability in both parameters allowed us
to perform GWAS and led to the identification of two genes, Stab2 and Vamp3, associated
with variation in hepatic ASO deposition, and another two, Rock2 and Adi1, that are associated
with variation in ASO potency. These results are particularly noteworthy as those four genes
are involved in either internalization and endosomal/lysosomal trafficking processes known to
be crucial for ASO uptake and subcellular localization [39, 44, 45]
Previous work has demonstrated Stab2 is capable of binding and internalizing PS MOE ASOs in
stabilin-expressing stable cell lines [28]. Additionally, immunostaining in wildtype mice displayed
high ASO accumulation in tissues that expressed Stab2 [28, 46]. Here we expand on these previous
findings and confirm the role of Stab2 in hepatic ASO uptake. First, GWAS and systems analysis
determined the Stab2 gene located within a peak SNP LD block, as well as locally regulated by the
presence of strong cis-eQTLs associated with the SNP haplotype. Second, HMDP strains with lower
Stab2 expression presented with significantly lower hepatic ASO accumulation when compared to
strains with more highly expressed Stab2. Third, ASO immunohistochemistry has previously demonstrated that liver sinusoidal endothelial cells (LSECs), a site of high hepatic Stab2 expression,
exhibited relatively high concentrations of ASO [47]. Finally, Stab2-/- mice accumulated significantly
less hepatic and splenic Malat1 ASO when compared to WT mice. Significantly, the differences in
Malat1 ASO uptake between Stab2-/- and WT were more pronounced in spleen, which has higher
Stab2 expression [28]. While this evidence demonstrates that Stab2 expression is critical in a subset
of cells for ASO uptake, that both the livers and spleens of Stab2-/- mice were capable of some ASO
accumulation and the existence of cell types capable of ASO uptake which don’t express Stab2 is evidence indicating the existence of Stab2-independent ASO uptake pathway(s) [48]. Surprisingly,
when we assessed Malat1 antisense drug potency in the WT and Stab2-/- mice, we did not see any
significant changes in hepatic Malat1 ASO potency. In fact, a recent study has demonstrated that
Scavenger Receptor B1 (Srb1) ASO had reduced potency in Stab2-/- when compared to wildtype
mice [41, 35]. A likely explanation for this discrepancy is the fact that, relative to Malat1, a larger
proportion of hepatic Srb1 mRNA expression is in LSEC cells versus hepatocytes [49, 39]. Thus,
ablation of Stab2 dependent uptake into LSECs would be expected to have more deleterious effect
on SRB1 ASO potency relative to the Malat1 ASO that targets a more hepatocyte localized mRNA.
While the current work does not address the mechanism for the disconnect between
hepatic Malat1 ASO accumulation and activity (S2 Fig), it is tempting to speculate that the
Stab2-mediated ASO uptake/internalization pathway is predominantly higher capacity and
lower affinity than other productive pathways [31, 41]. This is further validated by our data
demonstrating that Stab2 is implicated in ASO uptake but not efficacy (Fig 3). These data are
consistent with evidence that there are numerous uptake/internalization pathways that can be
broadly categorized as productive and non-productive with regards to antisense pharmacology
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Fig 7. Identification and validation of Rock2 in ASO activity. (A) Distribution of hepatic Malat1 expression based on genotype
distribution at rs29210579. Box and whisker plot depicting mean and distribution, unpaired t-test, � p�0.05 (B) Distribution of basal
hepatic Malat1 expression based on genotype distribution at rs29210579. Box and whisker plot depicting mean and distribution. (C)
Chromosome 12 plot for Rock2 displaying all significant SNPs (-log10 of p) for ASO efficacy. Red arrow indicates position of gene. (D)
MHT cells were incubated with Malat1 ASO and control ASO in presence and absence of 20 μM Y27632. After 24 hrs, Malat1 ASO
potency was assessed in all samples. MHT cells exhibit lower reduction in Malat1 expression with Y27632 as compared to PBS. Data
shows mean ± S.E.M (% control ASO) with two-way ANOVA and Bonferroni’s multiple comparison test. � p� 0.05.
https://doi.org/10.1371/journal.pgen.1007732.g007

[14]. To better understand the relationship between ASO accumulation and activity, we compared ASO liver accumulation and potency in the 100 strains and found that there was no correlation (S7 Fig). This lack of hepatic accumulation-activity correlation further supports the
existence of multiple ASO uptake pathways, and that these pathways have varying levels of efficacy in delivering the ASO to its target RNA.
Rho-kinase (Rock2) is one of the serine/threonine kinases functioning as a downstream effector molecule of small GTPase RhoA promoting contractile force generation and morphological
changes in cells and organs. Rock2 has been shown previously to promote acto-myosin contractility and tubulin polymerization by either directly phosphorylating the myosin regulatory light
chain (MLC) and the myosin binding subunit (MYPT1) of the MLC phosphatase or phosphorylating LIM kinases-1 and –2 (LIMK1 and LIMK2) [50–53]. Rock2 activity is known to play a role
in the movement of endosomal and lysosomal vesicles [54, 55]. One gene that has been shown to
be significant in the productive endosomal trafficking of ASO is Anxa2, a phospholipid binding
protein that is required for the biogenesis of late endosomes [56]. Studies have shown that Anxa2is
able to bind ASOs, and upon incubation of ASOs with cells ANXA2 was enriched in late endosomes, suggesting that Anxa2is important for intracellular conveyance of ASOs [42]. Interestingly,
Rock activity is essential for several ANAX2 signaling pathways [57, 58]. Even though the interactions of Anxa1 and Rock2 on ASO activity remain unclear, it suggests that factors affecting endosomal trafficking are important for productive ASO uptake.
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Fig 8. Identification and validation of Adi1 in ASO activity. (A) Chromosome 8 plot for Adi1 displaying all significant SNPs (-log10p) for ASO efficacy on
chromosome 8. Red arrow indicates position of gene (B) Plot of hepatic Adi1 expression and hepatic potency of 556089 shows differential Adi1 expression among
the HMDP strains. Low expressing strains are indicated in grey. (C) HMDP strains with lower hepatic Adi1 expression show higher potency compared to strains
with higher hepatic Adi1 expression. ���� p � 0.0001, unpaired t-test (D) Adi1 expression in MHT cells treated with either control siRNA or Adi1 siRNA. Data
shows mean mean ± S.E.M ��� p < 0.001, unpaired t-test (E) Plot of Malat ASO efficacy across indicated doses in MHT cells treated with Control siRNA or Adi1
siRNA. Data shows significant differences in ASO activity at 25 and 50nM Malat1 ASO, multiple t-tests using the Holm-Sidak method, with alpha = 0.05. �
p � 0.05.
https://doi.org/10.1371/journal.pgen.1007732.g008

In summary, genetic factors have been shown for the first time to be capable of altering the
hepatic ASO accumulation and activity of Malat1 cET ASO in vivo. Here we establish the utility of HMDP in identifying genes affecting the uptake and potency properties of ASOs; future
work must focus on translating these findings to human systems. Future studies will include
using in vitro and in vivo model systems to understand the specific mechanism(s) of action of
these identified genes in ASO uptake and/or intracellular trafficking. Finally, further studies
evaluating the factors affecting potency and uptake in disease models will provide us with a
more concise understanding of ASO response spectrum across populations and will help us
design more effective drugs with improved therapeutic benefits.

Materials and methods
Ethics statement
Ionis is AAALAC accredited and follows the 8th Ed. Of the Guide for the Care and Use of Laboratory Animals and the 2013 AVMA guidelines for the euthanasia of animals. All animals in
this study were anesthetized with Isoflurane and euthanized via cervical dislocation. The Ionis
IACUC-approved protocol is # P-0225. This protocol was approved on 5/28/2014.
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Oligonucleotide synthesis and delivery
2´, 4´- constrained 2´-O-ethyl (cEt) ASOs were synthesized at Ionis Pharmaceuticals (Carlsbad, CA) as described previously [59]. The Malat1 (ION 556089) and control (ION 549144)
ASOs were formulated in saline, and injected via subcutaneous administration into the animals. In order to monitor reproducibility of the subcutaneous dosing, we used C57BL/6J mice
as the control strain for each experiment. Similar levels of Malat1 inhibition in the livers were
observed for each experiment (S8 Fig).

Mice
Mice were obtained from The Jackson Laboratory and housed at Ionis Pharmaceuticals (Carlsbad, CA), maintained on a chow diet and entered into studies before they exceeded 7 weeks of
age. Stabilin-2 knockout (Stab2-/-) mice, developed as described in Hirose et.al. 2012 [60],
were purchased from Riken BioResource Center. At the end of each experiment, mice were
anesthetized, euthanized by cervical dislocation and blood was collected by cardiac puncture.
Spleens and livers were harvested and immediately snap frozen in liquid nitrogen for mRNA
expression analysis and histology. As many antisense drugs target liver [37, 61], our main analytical endpoints were hepatic drug accumulation and reduction of Malat 1 liver mRNA
expression. Despite the hepatic abundance of Malat1, its loss of function has been found to be
phenotypically silent, with no effect on global gene expression, phosphorylation, splicing factor
levels or pre-mRNA splicing events [46, 62]. A dose response study of Malat1 ASO performed
in 3 classic inbred strains (S9 Fig) determined the ED50 to be approximately 2 mg/kg. ASO tolerability and hepatotoxicity were assessed by measurement of serum aminotransferase (ALT
and AST) and spleen weights (S10A, S10B and S10C Fig). Although significant baseline variability was observed in the serum ALT/AST levels and spleen weights, no post-dose elevations
in either parameters were observed in any strains.

Cell lines and reagents
MHT cells were cultured in DMEM supplemented with 10% fetal bovine serum, streptomycin
(0.1 mg/ml), and penicillin (100 U/ml) as previously described [35]. Malat1 and control ASOs,
and the ROCK inhibitor Y27632 (Tocris, Cat. No. 1254) were added to cells at the indicated
concentrations for 24 hours. 5 nmole of Silencer select siRNA (Ambion, Negative Control #1,
Lpin1 –s66131, ADI1 –s75892 and 186988, VAMP3 –s98387 and s98386) was formulated in
RNAiMAX plus Opti-MEM (ThermoFisher Scientific) and incubated with cells for 48 hrs.
shRNA targeting Vamp3 was purchased from Origene (Cat. Nos. scrambled control:
TR30021V, Vamp3_1: TL515358VC, Vamp3_2: TL515358VD). MHT cells cultured as
described to a 50% confluency were exposed to 20uL viral particles for 24hrs. Cells were
washed and selected with 1ug/mL Puromycin (Sigma Aldritch, Cat. No. P8833) for 10 days,
then colonies were selected and plated in a 96 well plate. Target knockdown was assessed by
QPCR and normalized to cyclophilin.

RNA analysis
Total mRNA was isolated using a QIAGEN RNAeasy kit (QIAGEN, Valencia, CA, USA).
Reduction of target mRNA expression was determined by qPCR using StepOne RT–PCR
machines (Applied Biosystems) as described previously [35]. Relative levels of Malat1 and
Lpin1 were normalized to Cyclophilin.
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Liver pharmacokinetic analysis
Pieces of whole liver were minced, weighed into individual wells, then homogenization buffer
[63] was added to those corresponding wells. Control tissue homogenate was made by adding
homogenization buffer at a 9 to 1 ratio to weighed amount of mouse untreated liver. Aliquots
and appropriate amounts of calibration standards were added into wells. Internal standard
and approximately 0.25cm3 granite beads were added and then extracted via a liquid-liquid
extraction with ammonium hydroxide and phenol: chloroform: isoamyl alcohol (25:24:1). The
aqueous layer was then further processed via solid phase extraction utilizing a Phenyl plate.
Eluates had a final pass through a protein precipitation plate before dry down under nitrogen
at 50˚C. Dried samples were reconstituted in water containing 100 μM EDTA. These samples
were injected into an Agilent LCMS instrument consisting of a 1260 binary pump, a 1200 isocratic pump, a column oven, an auto sampler, and a 6130 single quadrupole mass spectrometer
for analysis (Agilent, Wilmington, DE, USA).

Association analysis
Since genetic association studies in inbred mice produce inflated false positive results owing to
population structure and genetic relatedness, it is essential to use appropriate statistical tests.
Efficient mixed model association (EMMA) utilizes linear mixed model with single dimensional optimization and phylogenetic control based kinship analysis to account for population
stratification [26]. EMMA enabled correction for the spurious associations helps to cut down
on the data processing time manifold. We identified genetic associations using the FastLMM,
which is a reformulated mixed model analysis that performs linearly in run time and memory
footprint for GWAS in very large data sets [27]. We retrieved the genotypes from UCLA systems genetics database along with chromosomal locations of linkage disequilibrium (LD)
blocks. The average LD block size for the HMDP is 2Mb. The blocks were calculated here
using Plink2’s implementation of the Haploview algorithm and appear to be smaller than average (S6 Table). The global gene expression microarrays which were generated from liver of
chow fed male mice from 95 HMDP strains, were obtained from the UCLA systems genetics
database and are available at NCBI GEO (GSE16780). These data were used to perform the cisand trans- analysis as previously described [30]. FastLMM on ASO accumulation and activity
properties was performed with a genome-wide significance threshold of 4.1 x 10−6 as described
[21–25, 30].

Statistics
Data are reported as means ± SEM. The statistical tests are mentioned in the figure legends.
Statistical significance was considered when p<0.05. Unpaired Student’s t-test or two-way
ANOVA and Bonferroni’s multiple comparison test have been used to determine significance
relative to control groups.

Supporting information
S1 Fig. Antisense oligonucleotides (ASO) used for this study. (A) Structural illustration of
cET ASOs and PS-MOE ASO showing the organic modifications in the 2’ and 4’ carbon of the
ribose moiety and (B) the full length sequence of each specific ASO used in the study.
(TIF)
S2 Fig. Hepatic Malat1 expression after Malat1 ASO dose in WT and Stab2-/- mice. Plot of
hepatic Stab2 expression and hepatic accumulation of Malat1 ASO. Red dots indicate the
strains with low hepatic Stab2 expression. These outlier strains with low hepatic Stab2
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expression were identified.
(TIF)
S3 Fig. Vamp3 expression regulates hepatic PK of Malat1 ASO. (A) Plot of hepatic Vamp3
expression and hepatic accumulation of Malat1 ASO in BXD strains. Grey dots indicate the
strains with low hepatic Vamp3 expression (B) Relative Vamp3 mRNA expression in MHT
cells after transduction with either scrambled control or Vamp3 targeting shRNA. Data shows
mean ± S.E.M � p � 0.05.
(TIF)
S4 Fig. Verification of hepatic Malat1 expression. (A) Liver tissue from AXB5/PgnJ and
BXD39/TyJ showing Malat1 expression (Malat1 staining is shown in red). AXB5/PgnJ shows
a higher reduction Malat1expression than BXD39/ TyJ which is commensurate with hepatic
potency of Malat1 ASO in the two strains. Scale = 50 um (B) 72 hour SD dose-response curve
in three classic inbred HMDP strains with 0.2, 0.7, 1.4, 2, 4, 6 and 8 mg/kg of Malat1 ASO. (C)
Hepatic Malat1 expression in three classic inbred HMDP strains with different time points of
incubation (6 hrs, 24 hrs, 48 hrs and 72 hrs) with Malat1 ASO. Data points are mean ± S.E.M.
(TIF)
S5 Fig. Relative hepatic Malat1 expression in 100 HMDP strains as compared to expression
in C57BL/6J strain. Significant variability was observed in basal hepatic Malat1 expression
levels among the 100 strains of HMDP as seen with single 2mg/kg Malat1 ASO dose after 72
hrs. Data points are mean ± S.E.M.
(TIF)
S6 Fig. Validation of Lpin1 and Rock2 inhibition after treatment with siRNAs and Y27632
and Malat1 ASO dose response curve in MHT-1 cells. (A) Inhibition of Lpin1 in MHT-1
cells after 48 hours incubation with 32 nM siRNA (B) Western blot analysis to confirm knockdown of Lipin1 (normalized to GAPDH) (C) MHT-1 cells were incubated with 25, 50, 100,
250, 500 and 1000 nM Malat1 ASO for 72 hours. The IC50 was calculated to be 216.5 nM. (D)
No significant change in Malat1 ASO potency observed with inhibition of Lpin1 with Lpin1
siRNA as compared to NS siRNA. (E) Western blot analysis confirms downregulation of
ROCK activity with significant decrease in pMLC2 levels. Quantification was normalized to
MLC2. Data represents mean ± S.E.M. � p � 0.05 �� p � 0.01, ��� p � 0.001, ���� p � 0.0001,
unpaired t-test.
(TIF)
S7 Fig. Correlation between Malat1 ASO hepatic potency and accumulation. Hepatic
potency and accumulation of Malat1 ASO, obtained post single dose of 2mg/kg ASO, in the
100 HMDP strains were correlated. No correlation was observed between hepatic PK and PD
of Malat1 ASO for 100 strains.
(TIF)
S8 Fig. Hepatic Malat1 expression in C57BL/6J. C57BL/6J animals were used in every experiment as a control strain to ensure reproducibility of data. 6 week old male C57/BL/6 animals
(n = 4/ strain/treatment) were administered a single dose of 2 mg/kg of ION 556089 (black
bar) or ION 549144 (grey bar). After 72 hours, gene expression was assessed in the harvested
livers. Similar trends in reduction of hepatic Malat1 expression (normalized to control ASO)
were obtained in most of the experiments. Data points are mean ± S.E.M.
(TIF)
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S9 Fig. Effective dose 50 (ED50) determination of Malat1 cET ASO in HMDP mice strains.
6 week male mice from Balb/cJ, C57BL6/J and 129x1/SvJ were (n = 5/strain/treatment) were
dosed subcutaneously with 1, 3, 5 and 10 mg/kg of either Control cET ASO (ION 549144) or
Malat1 cET ASO (ION 556089). Hepatic Malat1 mRNA expression was assessed 72 hours post
injection using qRTPCR and results are presented as mean ± S.E.M.
(TIF)
S10 Fig. Serum aminotransferase and spleen weights after ASO administration in HMDP
strains. (A) Alanine transaminase (ALT) and Aspartate transaminase (B) levels in serum and
(C) spleen weights in the 100 inbred strains after 2mg/kg single dose of Malat1 ASO as compared to Control ASO, 72 hrs post-injection. Data points are mean ± S.E.M.
(TIF)
S1 Table. cis and trans eQTLs associated with Chromosome 4 SNP rs32062485, p = 4.1x10-6.
(PDF)
S2 Table. cis and trans eQTLs associated with Chromosome 10 SNP rs29364476,
p = 4.1x10-6.
(PDF)
S3 Table. cis and trans eQTLs associated with Chromosome 4 SNP rs27549337, p = 4.1x10-6.
(PDF)
S4 Table. cis and trans eQTLs associated with Chromosome 4 SNP rs29210579, p = 4.1x10-6.
(PDF)
S5 Table. cis and trans eQTLs associated with Chromosome 4 SNP rs29212236, p = 4.1x10-6.
(PDF)
S6 Table. LD blocks surrounding the indicated SNPs using Plink2’s implementation of the
Haploview algorithm.
(PDF)
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